Citations

Showing 10 of 108094 citations.

Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
Schiff, David , Jaeckle, Kurt A. , Anderson, S. Keith , Buckner, Jan C. , Stella, Phillip J., Flynn, Patrick J. , Schwerkoske, John F., Kaluza, Vesna, Twohy, Erin , Dancey, Janet, Wright, John, Schiff, David , Galanis, Evanthia , Giannini, Caterina , Erickson, Bradley J. , Wright, John, Sarkaria, Jann N.

Mayo Clinic

Cancer | January 3, 2018 | Volume: 124 | Issue: 7 | Pages: 1455-1463

10.1002/cncr.31219 | PMID 29313954 Get It

BACKGROUNDMitogen‐activated protein kinase (MAPK) activation and mammalian target of rapamycin (mTOR)‐dependent signaling are hallmarks of glioblastoma. In the current study, the authors conducted a phase 1/2 study of sorafenib (an inhibitor of Raf kinase and vascular endothelial growth factor receptor 2 [VEGFR‐2]) and the mTOR inhibitor temsirolimus in patients with recurrent glioblastoma.METHODSPatients with recurrent glioblastoma who developed disease progression after surgery or radiotherapy plus temozolomide and with ≤2 prior chemotherapy regimens were eligible. The phase 1 endpoint was the maximum tolerated dose (MTD), using a cohorts‐of‐3 design. The 2‐stage phase 2 study included separate arms for VEGF inhibitor (VEGFi)–naive patients and patients who progressed after prior VEGFi.RESULTSThe MTD was sorafenib at a dose of 200 mg twice daily and temsirolimus at a dose of 20 mg weekly. In the first 41 evaluable patients who were treated at the phase 2 dose, there were 7 who were free of disease progression at 6 months (progression‐free survival at 6 months [PFS6]) in the VEGFi‐naive group (17.1%); this finding met the prestudy threshold of success. In the prior VEGFi group, only 4 of the first 41 evaluable patients treated at the phase 2 dose achieved PFS6 (9.8%), and this did not meet the prestudy threshold for success. The median PFS for the 2 groups was 2.6 months and 1.9 months, respectively. The median overall survival for the 2 groups was 6.3 months and 3.9 months, respectively. At least 1 adverse event of grade ≥3 was observed in 75.5% of the VEGFi‐naive patients and in 73.9% of the prior VEGFi patients.CONCLUSIONSThe limited activity of sorafenib and temsirolimus at the dose and schedule used in the current study was observed with considerable toxicity of grade ≥3. Significant dose reductions that were required in this treatment combination compared with tolerated single‐agent doses may have contributed to the lack of efficacy. Cancer 2018;124:1455‐63. © 2018 American Cancer Society.
Meta-analysis of a 10-plex urine-based biomarker assay for the detection of bladder cancer
Masuda, Norihiko , Park, Meyeon , Liu, Alvin Y., Goodison, Steve , Dai, Yunfeng , Kozai, Landon, Furuya, Hideki , Rosser, Charles J. , Furuya, Hideki , Ogawa, Osamu , Lotan, Yair , Kobayashi, Takashi

Mayo Clinic

Oncotarget | January 3, 2018 | Volume: 9 | Issue: 6 | Pages: 7101-7111

10.18632/oncotarget.23872 | PMID 29467953 Get It

Low‐grade fibromyxoid sarcoma arising within the median nerve
Swanson, Amy A. , Giannini, Caterina , Folpe, Andrew L. , Dyke, Daniel L. Van , Amrami, Kimberly K. , Michalak, William A., Van Dyke, Daniel L, Vaubel, Rachael A. , Giannini, Caterina

Mayo Clinic

Neuropathology | January 3, 2018 | Volume: 38 | Issue: 3 | Pages: 309-314

10.1111/neup.12453 | PMID 29314300 Get It

We report a case of low‐grade fibromyxoid sarcoma arising within the median nerve. A 31‐year‐old woman presented with symptoms of carpal tunnel syndrome and an enlarging mass in her right palm over 1 year. MRI demonstrated a mass associated with the right median nerve with solid and cystic components. At surgery, the mass was located within the epineurium, could be bluntly dissected from the nerve fascicles, and was suspected to be a schwannoma. A 3.4 cm, tan‐pink, glistening, smooth, homogenous mass was submitted to pathology. Microscopically, the tumor was a solid and cystic circumscribed nodule with a dense fibrous pseudocapsule. The tumor cells were uniformly bland and spindle‐shaped, with small, hyperchromatic oval nuclei and were embedded in an alternating fibrous and myxoid stroma with a prominent curvilinear vasculature and perivascular sclerosis. The differential diagnosis for this lesion included myxoid neurofibroma, schwannoma, soft tissue perineurioma, low‐grade malignant peripheral nerve sheath tumor and low‐grade fibromyxoid sarcoma. The tumor cells expressed MUC4, GLUT‐1, and vimentin and were negative for S‐100 protein, epithelial membrane antigen, smooth muscle actin, desmin, claudin‐1, neurofilament and SOX10. Fluorescence in situ hybridization, with a break‐apart probe strategy, demonstrated FUS rearrangement, consistent in this morphological context with the low‐grade fibromyxoid sarcoma‐associated FUS‐CREB3L2 or FUS‐CREB3L1 fusions. Low‐grade fibromyxoid sarcoma is exceptionally rare in the peripheral nerve, with only a single previously reported case. Nonetheless, as our case illustrates, this entity must be included in the differential diagnosis of unusual intraneural mesenchymal tumors. As in all other locations, intraneural low‐grade fibromyxoid sarcomas should be excised with negative margins. Patients with this disease require long‐term clinical follow‐up, given this tumor's propensity for very late distant metastases to the lungs and other sites.
Ethical Considerations Related to Return of Results from Genomic Medicine Projects: The eMERGE Network (Phase III) Experience
Fossey, Robyn, Kochan, David C., Winkler, Erin, Pacyna, Joel E. , Thibodeau, Stephen N. , Connolly, John J. , Harr, Margaret , Behr, Meckenzie, Prows, Cynthia A. , Cobb, Beth L., Myers, Melanie F. , Leslie, Nancy, Namjou‐Khales, Bahram, Rasouly, Hila Milo , Wynn, Julia , Fedotov, Alexander , Gharavi, Ali G. , Williams, Janet L. , Pais, Lynn , Holm, Ingrid A. , Aufox, Sharon , Smith, Maureen E. , Scrol, Aaron, Leppig, Kathleen A. , Jarvik, Gail P. , Wiesner, Georgia L. , Li, Rongling, Stroud, Mary , Sharp, Richard R. , Kochan, David, Thibodeau, Stephen, Myers, Melanie F , Holm, Ingrid A , Sharp, Richard R , Milo Rasouly, Hila , Jarvik, Gail P , Connolly, John J , Olson, Janet E. , Chung, Wendy K. , Smoller, Jordan W. , Kullo, Iftikhar J.

Mayo Clinic

Journal of Personalized Medicine | January 3, 2018 | Volume: 8 | Issue: 1 | Pages: 2

10.3390/jpm8010002 | PMID 29301385 Get It

We examined the Institutional Review Board (IRB) process at 9 academic institutions in the electronic Medical Records and Genomics (eMERGE) Network, for proposed electronic health record-based genomic medicine studies, to identify common questions and concerns. Sequencing of 109 disease related genes and genotyping of 14 actionable variants is being performed in ~28,100 participants from the 9 sites. Pathogenic/likely pathogenic variants in actionable genes are being returned to study participants. We examined each site’s research protocols, informed-consent materials, and interactions with IRB staff. Research staff at each site completed questionnaires regarding their IRB interactions. The time to prepare protocols for IRB submission, number of revisions and time to approval ranged from 10–261 days, 0–11, and 11–90 days, respectively. IRB recommendations related to the readability of informed consent materials, specifying the full range of potential risks, providing options for receiving limited results or withdrawal, sharing of information with family members, and establishing the mechanisms to answer participant questions. IRBs reviewing studies that involve the return of results from genomic sequencing have a diverse array of concerns, and anticipating these concerns can help investigators to more effectively engage IRBs.
Clinical Implementation of Robust Optimization for Craniospinal Irradiation
Tasson, A , Laack, Nadia N., Beltran, Chris , Tasson, Alexandria , Beltran, Chris J

Mayo Clinic

Cancers | January 3, 2018 | Volume: 10 | Issue: 1 | Pages: 7

10.3390/cancers10010007 | PMID 29301336 Get It

With robust optimization for spot scanning proton therapy now commercially available, the ability exists to account for setup, range, and interfield uncertainties during optimization. Robust optimization is particularly beneficial for craniospinal irradiation (CSI) where the large target volume lends itself to larger setup uncertainties and the need for robust match lines can all be handled with the uncertainty parameters found inside the optimizer. Suggested robust optimization settings, parameters, and image guidance for CSI patients using proton therapy spot scanning are provided. Useful structures are defined and described. Suggestions are given for perturbations to be entered into the optimizer in order to achieve a plan that provides robust target volume coverage and critical structure sparing as well as a robust match line. Interfield offset effects, a concern when using multifield optimization, can also be addressed within the robust optimizer. A robust optimizer can successfully be employed to produce robust match lines, target volume coverage, and critical structure sparing under specified uncertainties. The robust optimizer can also be used to reduce effects arising from interfield uncertainties. Using robust optimization, a plan robust against setup, range, and interfield uncertainties for craniospinal treatments can be created. Utilizing robust optimization allows one to ensure critical structures are spared and target volumes are covered under the desired uncertainty parameters.
Impact of Patient Reminders on Papanicolaou Test Completion for High-Risk Patients Identified by a Clinical Decision Support System
MacLaughlin, Kathy L. , Kessler, Maya , Elayavilli, Ravikumar Komandur, Hickey, Branden C., Scheitel, Marianne, Kremers, Walter K. , Chaudhry, Rajeev , Kessler, Maya E, Komandur Elayavilli, Ravikumar, Scheitel, Marianne R, Wagholikar, Kavishwar B. , Liu, Hongfang , Kremers, Walter K

Mayo Clinic

Journal of Women's Health | January 3, 2018 | Volume: 27 | Issue: 5 | Pages: 569-574

10.1089/jwh.2017.6667 | PMID 29297754 Get It

Background: A clinical decision support system (CDSS) for cervical cancer screening identifies patients due for routine cervical cancer screening. Yet, high-risk patients who require more frequent screening or earlier follow-up to address past abnormal results are not identified. We aimed to assess the effect of a complex CDSS, incorporating national guidelines for high-risk patient screening and abnormal result management, its implementation to identify patients overdue for testing, and the outcome of sending a targeted recommendation for follow-up. Materials and Methods: At three primary care clinics affiliated with an academic medical center, a reminder recommending an appointment for Papanicolaou (Pap) testing or Pap and human papillomavirus cotesting was sent to high-risk women aged 18 through 65 years (intervention group) identified by CDSS as overdue for testing. Historical control patients, who did not receive a reminder, were identified by CDSS 1 year before the date when reminders were sent to the intervention group. Test completion rates were compared between the intervention and control groups through a generalized estimating equation extension. Results: Across the three sites, the average completion rate of recommended follow-up testing was significantly higher in the intervention group at 23.7% (61/257) than the completion rate at 3.3% (17/516) in the control group ( p < 0.001). Conclusions: A CDSS with enhanced capabilities to identify high-risk women due for cervical cancer testing beyond routine screening intervals, with subsequent patient notification, has the potential to decrease cervical precancer and cancer by improving adherence to guideline-compliant follow-up and needed treatment.
Neuropathology of autonomic dysfunction in synucleinopathies
Cutsforth‐Gregory, Jeremy K. , Benarroch, Eduardo E. , Cutsforth-Gregory, Jeremy K., Coon, Elizabeth A.

Mayo Clinic

Movement Disorders | January 3, 2018 | Volume: 33 | Issue: 3 | Pages: 349-358

10.1002/mds.27186 | PMID 29297596 Get It

Abstract The synucleinopathies—Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure—result from distinct patterns of abnormal α‐synuclein aggregation throughout the nervous system. Autonomic dysfunction in these disorders results from variable involvement of the central and peripheral autonomic networks. The major pathologic hallmark of Parkinson's disease and dementia with Lewy bodies is Lewy bodies and Lewy neurites; of multiple system atrophy, oligodendroglial cytoplasmic inclusions; and of pure autonomic failure, peripheral neuronal cytoplasmic inclusions. Clinical manifestations include orthostatic hypotension, thermoregulatory dysfunction, gastrointestinal dysmotility, and urogenital dysfunction with neurogenic bladder and sexual dysfunction. Strong evidence supports isolated idiopathic rapid eye movement sleep disorder as a significant risk factor for the eventual development of synucleinopathies with autonomic and/or motor involvement. In contrast, some neurologically normal elderly individuals have Lewy‐related pathology. Future work may reveal protective or vulnerability factors that allow some patients to harbor Lewy pathology without overt autonomic dysfunction. © 2018 International Parkinson and Movement Disorder Society
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HE
Cramer, Paula , Fraser, Graeme , Santucci-Silva, Rodrigo, Grosicki, Sebastian , Dilhuydy, Marie‐Sarah, Janssens, Ann , Loscertales, Javier , Rule, Simon , Traina, Shana, Chan, Eric K. H., Diels, Joris , Sengupta, Nishan , Mahler, Michelle, Salman, Mariya, Howes, Angela, Chanan‐Khan, Asher , Chanan-Khan, Asher, Dilhuydy, Marie‐Sarah, Goy, Andre Henri

Mayo Clinic

Leukemia & Lymphoma | January 3, 2018 | Volume: 59 | Issue: 9 | Pages: 2075-2084

10.1080/10428194.2017.1416364 | PMID 29295653 Get It

Special K with No License to Kill: Accidental Ketamine Overdose on Induction of General Anesthesia
Warner, Lindsay L. , Smischney, Nathan, Smischney, Nathan J.

Mayo Clinic

American Journal of Case Reports | January 3, 2018 | Volume: 19 | Issue: No issue available | Pages: 10-12

10.12659/ajcr.906205 | PMID 29295971 Get It

Medical Assistance in Dying—Unanswered Questions
Verheijde, Joseph L., Rady, Mohamed Y.

Mayo Clinic

JAMA Internal Medicine | January 2, 2018 | Volume: 178 | Issue: 1 | Pages: 155

10.1001/jamainternmed.2017.7313 | PMID 29297017 Get It